Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (181-190 of 264) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 26, 2025
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trialGiacomo Biganzoli, Edoardo Isnaldi, François Richard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 StudySigne Borgquist, Anita Giobbie-Hurder, Thomas P Ahern, et al.
The New England Journal of Medicine|October 23, 2018
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C Turner, Dennis J Slamon, Jungsil Ro, et al.
JCO Precision Oncology|September 10, 2021
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and RibociclibAditya Bardia, Fei Su, Nadia Solovieff, et al.
Future Oncology (London, England)|February 7, 2020
Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary reviewGiovanni Corso, Francesca Magnoni, Elena Provenzano, et al.
The Lancet. Oncology|February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trialSherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
The New England Journal of Medicine|June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialDiana Crivellari, Kathryn P Gray, Silvia Dellapasqua, et al.
Cancer Cell|September 6, 2008
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agentsYuval Shaked, Erik Henke, Jeanine M L Roodhart, et al.
Breast Cancer Research : BCR|November 10, 2016
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trialHarriet Johansson, Kathryn P Gray, Olivia Pagani, et al.
Pageof 27

Showing results (181-190 of 264) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|April 26, 2025
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trialGiacomo Biganzoli, Edoardo Isnaldi, François Richard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 StudySigne Borgquist, Anita Giobbie-Hurder, Thomas P Ahern, et al.
The New England Journal of Medicine|October 23, 2018
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C Turner, Dennis J Slamon, Jungsil Ro, et al.
JCO Precision Oncology|September 10, 2021
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and RibociclibAditya Bardia, Fei Su, Nadia Solovieff, et al.
Future Oncology (London, England)|February 7, 2020
Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary reviewGiovanni Corso, Francesca Magnoni, Elena Provenzano, et al.
The Lancet. Oncology|February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trialSherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
The New England Journal of Medicine|June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialDiana Crivellari, Kathryn P Gray, Silvia Dellapasqua, et al.
Cancer Cell|September 6, 2008
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agentsYuval Shaked, Erik Henke, Jeanine M L Roodhart, et al.
Breast Cancer Research : BCR|November 10, 2016
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trialHarriet Johansson, Kathryn P Gray, Olivia Pagani, et al.
Pageof 27